TRI102
Drugformulation containing active moiety (amphetamine)
Other names: amphetamine extended-release oral suspension
NCT Number: NCT02083783
The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.
Looking for future studies?
Notify Me6 year–12 year
All sexes
Interventional
Phase 3
Newport Beach Clinical Research Associates, Inc., Newport Beach, California, United States
A Phase 3, randomized, double-blind, placebo-controlled, parallel group, multicenter, laboratory classroom study. After Screening and Baseline evaluations, eligible subjects are enrolled in the study and entered the open-label phase, dose-optimization phase. TRI102 is taken once daily and subjects undergo dose optimization activities for 5 weeks.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
formulation containing active moiety (amphetamine)
Other names: amphetamine extended-release oral suspension
formulation without active moiety
Time frame: Absolute change from baseline in SKAMP-C score from baseline to 4 hours after dose
Change from baseline in SKAMP-Combined Scores measured approximately 4 hours after dose (active or placebo). The SKAMP-Combined score is obtained by summing 13 assessment items, where each item is rated on a 7-point scale (0 = normal to 6 = maximal impairment). This gives an overall (combined) SKAMP Score of 0= normal to 78 which indicates maximal impairment. The endpoint is assessed as a change from baseline in the overall score on the 78-point scale.
Time frame: Absolute change from baseline in PERMP questions answered correctly, measured from baseline to 4 hours postdose.
The PERMP is a math test that measures effortful performance without a learning curve (Wigal and Wigal 2006). The test determines the number of problems attempted and the number of problems correctly answered. In this study, the primary efficacy measure was a PERMP evaluation done 4 hours after taking study medication, a time selected a priori to coincide with the known pharmacodynamic effects based on prior research and to minimize the impact of repeated measures on adjustment of multiplicity (Wigal et al. 1998; Pelham et al. 2001). The PERMP consists of 400 math questions and each are scored. PERMP scores are expressed as the number of questions correct. Predose PERMP Tests are compared with post-dose PERMP scores at prespecfied timepoints.
Tris Pharma, Inc.
Industry
TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01876524
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Cartagena, Murcia, Spain
View Trial DetailsNCT06679010
Anxiety, Anxiety Disorders
Odense, Denmark
View Trial DetailsNCT02364817
Alcohol-Related Disorders, Alcoholism
Bron, France
View Trial DetailsNCT07253441
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Lenexa, Kansas, United States
View Trial Details